A
Avery L. Gaymon
Researcher at University of Pennsylvania
Publications - 6
Citations - 898
Avery L. Gaymon is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Internal medicine & Immunology. The author has an hindex of 3, co-authored 4 publications receiving 428 citations.
Papers
More filters
Journal ArticleDOI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer,Joseph A. Fraietta,Megan M. Davis,Adam D. Cohen,Kristy L. Weber,Eric Lancaster,Patricia A. Mangan,Irina Kulikovskaya,Minnal Gupta,Fang Chen,Lifeng Tian,Vanessa E. Gonzalez,Jun Xu,In-Young Jung,J. Joseph Melenhorst,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Avery L. Gaymon,Stephanie Desjardins,Anne Lamontagne,January Salas-Mckee,Andrew D. Fesnak,Don L. Siegel,Bruce L. Levine,Julie K. Jadlowsky,Regina M. Young,Anne Chew,Wei-Ting Hwang,Elizabeth O. Hexner,Beatriz M. Carreno,Christopher L. Nobles,Frederic D. Bushman,Kevin R. Parker,Yanyan Qi,Ansuman T. Satpathy,Howard Y. Chang,Yangbing Zhao,Simon F. Lacey,Carl H. June +40 more
TL;DR: This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
Journal ArticleDOI
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle V. Frey,Saar Gill,Elizabeth O. Hexner,Stephen J. Schuster,Sunita D. Nasta,Alison W. Loren,Jakub Svoboda,Edward A. Stadtmauer,Daniel J. Landsburg,Anthony R. Mato,Bruce L. Levine,Simon F. Lacey,J. Joseph Melenhorst,Elizabeth Veloso,Avery L. Gaymon,Edward Pequignot,Xinhe Shan,Wei-Ting Hwang,Carl H. June,David L. Porter +19 more
TL;DR: Attainment of a CR after CART-19 infusion, regardless of cell dose, is associated with longer OS and progression-free survival in patients with relapsed CLL, and a 5 × 108 dose of Cart-19 may be more effective at inducing CR without excessive toxicity.
Journal ArticleDOI
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
Saar Gill,Noelle V. Frey,Elizabeth O. Hexner,Susan Metzger,M. O'brien,Wei-Ting Hwang,Jennifer Brogdon,Megan M. Davis,Joseph A. Fraietta,Avery L. Gaymon,Whitney L. Gladney,Simon F. Lacey,Anne Lamontagne,Anthony R. Mato,Marcela V. Maus,J. Joseph Melenhorst,Edward Pequignot,Marco Ruella,Maksim Shestov,John C. Byrd,Stephen J. Schuster,Don L. Siegel,Bruce L. Levine,Carl H. June,David L. Porter +24 more
TL;DR: In CLL patients not achieving a CR despite at least 6 months of ibrutinib, adding huCART-19 mediated a high rate of deep and durable remissions.
Journal ArticleDOI
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
Edward A. Stadtmauer,Adam D. Cohen,Kristy L. Weber,Simon F. Lacey,Vanessa E. Gonzalez,J. Joseph Melenhorst,Joseph A. Fraietta,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Patricia A. Mangan,Avery L. Gaymon,Stephanie Desjardins,Eric Lancaster,January Salas-Mckee,Megan M. Suhoski,Andrew D. Fesnak,Matthew O'Rourke,Anne Lamontagne,Don L. Siegel,Regina M. Young,Anne Chew,Christopher L. Nobles,Frederic D. Bushman,Howard Y. Chang,Ansuman T. Satpathy,Yangbing Zhao,Wei-Ting Hwang,Elizabeth O. Hexner,Carl H. June +30 more
TL;DR: Tmunity: Membership on an entity's Board of Directors or advisory committees, Research Funding; novartis: Research Funding, other: scientific founder, for which he has founders stock but no income, Patents & Royalties.
Journal ArticleDOI
A phase I trial of cyclosporine for hospitalized patients with COVID-19
Emily A. Blumberg,Julia Poll,Pablo Tebas,Joseph A. Fraietta,Ian Frank,Amy Marshall,Anne Chew,Elizabeth Veloso,Alison Carulli,Walter Rogal,Avery L. Gaymon,Aliza Schmidt,Tiffany Barnette,Renee Jurek,Rene Martins,Brian Hudson,Kalyan D. Chavda,Christina Bailey,Sarah E. Church,Hooman Noorchashm,Wei-Ting Hwang,Carl H. June,Elizabeth O. Hexner +22 more
TL;DR: Short courses of CSA appear safe and feasible in patients with COVID-19 who require oxygen and may be a useful adjunct in resource-limited health care settings.